GSK enquiries:
|
|
|
|
UK Media enquiries:
|
Simon Steel
|
+44 (0) 20 8047 5502
|
(London)
|
|
Tim Foley
|
+44 (0) 20 8047 5502
|
(London)
|
Analyst/Investor enquiries:
|
Sarah Elton-Farr
|
+44 (0) 208 047 5194
|
(London)
|
|
Jeff McLaughlin
|
+1 215 751 7002
|
(Philadelphia)
|
Cautionary statements regarding forward-looking
statementsGSK cautions
investors that any forward-looking statements or projections made
by GSK, including those made in this announcement, are subject to
risks and uncertainties that may cause actual results to differ
materially from those projected. Such factors include, but are not
limited to, those described under Item 3.D Principal risks and
uncertainties in the company's Annual Report on Form 20-F for
2017.
|
|
Registered in England & Wales:
No. 3888792
|
|
|
|
Registered Office:
980 Great West Road
Brentford, Middlesex
TW8 9GS
|
|
|
GlaxoSmithKline plc
|
|
(Registrant)
|
|
|
Date: February
22, 2019
|
|
|
|
|
By: VICTORIA
WHYTE
--------------------------
|
|
|
|
Victoria Whyte
|
|
Authorised
Signatory for and on
|
|
behalf
of GlaxoSmithKline plc
|